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Summary 
  Among three major diisocyanates: TDI, methylenediphenyl diisocyanate (MDI) and 
hexamethylene diisocyanate (HDI), TDI has been regarded as the leading cause of 
diisocyanate-induced asthma. The principal feature of TDI-induced asthma is the airway 
inflammation with influx of neutrophils, lymphocytes and eosinophils. This in turn leads to 
the variable airway hyper-responsiveness. TDI-induced asthma can share many similar 
features with allergic asthma, such as increased total and specific IgE serum levels, activated 
CD4+ T cells, eosinophils and mast cells, increased levels of IL-4 and IL-5 and airway 
remodeling. 
  So far, the pathogenic mechanism of TDI-induced asthma is still far from clear. It has 
been commonly accepted that TDI sensitization involves binding of TDI to carrier 
molecules. Specific IgE to diisocyanate has been regarded to be helpful in the diagnosis of 
occupational asthma. Particularly, increased immunoglobulin IgG1 was suggested to be 
associated to TDI exposure and the protein-conjugated TDI can be a useful marker for 
progress of TDI-asthma. In the past decades, the reports on the phenotype of immune 
response to TDI have been quite controversial. Maestrelli et al. reported that increased levels 
of Th2 cytokines were detected in the airways and bronchial mucosa of TDI asthmatics. 
However, some authors such as Lummus et al. observed Th1-like response characterized by 
an increase in the number of neutrophils and the levels of IFN-Ȗ and IL-8.  
  In order to better address those issues, we established a TDI BALB/c mouse model by 
subcutaneous sensitization and intranasal challenge to investigate the inflammatory and 
immune responses that occurred in the development of TDI-induced asthma. In this model, 
the Th2 mode was involved since the TDI mice demonstrated Th2-like immune responses 
with significantly increased serum total IgE, IL-4 and decreased IFN-Ȗ. Airway remodeling 
was initiated in the early phase of the development of the TDI asthma. However, neutrophil-
dominant pulmonary inflammation in TDI-induced mouse model of asthma suggested a 
different inflammatory phenotype from the eosinophil-dominant allergic responses induced 
by high molecular weight chemicals, such as OVA and OVA 323-339. 
  There are several different routes of exposure from which the professional workers finally 
could develop asthma. The skin might function as one of most possible initiative site for 
 10 
 
sensitization and later on, the final target tissue, airways became hyper-sensitive and asthma 
occurred. In this context, the improved mouse model by repeated epicutaneous sensitization 
and intranasal challenge was established. Similar inflammatory and immune responses were 
triggered as in the mice by subcutaneous sensitization. Furthermore, followed by exposure to 
TDI, increased airway hypersensitivity was observed when indicated by Penh with the 
method of plethysmography. It seems that IgG1 may not be ignored as well as IgE in the 
development of TDI-induced asthma, at least in mouse model of asthma.  
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1. Introduction 
  Occupational asthma is the most commonly reported occupational lung disease in many 
industrialized countries [1-2]. Occupational exposure has been shown to induce both 
respiratory and contact hypersensitivity reactions [3-5]. Diisocyanates, highly reactive low 
molecular weight compounds (LMW), are widely used in the polyurethane industry. 
Diisocyanates have been widely used for manufacture of polyurethane foams, coatings, 
elastomers, adhesives and many other products [6]. With the increasing demand, the 
diisocyanate production has been in steady rise for decades [1, 3]. Diisocyanates have been 
reported as one of the leading causes of occupational asthma, among which TDI, MDI and 
HDI are the most common triggers. Estimates on the prevalence of isocyanate-induced 
asthma among exposed workers varies from 0-15% [3, 7]. The principal feature of TDI-
induced asthma is the airway inflammation with influx of lymphocytes, eosinophils and 
neutrophils [8]. This in turn leads to the variable airway hyper-responsiveness (AHR). 
Furthermore, many features with allergic asthma, such as elevated total and specific IgE 
serum levels, airway inflammation characterized by activated CD4+ T cells, eosinophils and 
mast cells, increased levels of IL-4 and IL-5 and airway remodeling can also be observed in 
most of TDI-induced asthma [9]. 
  Murine models have been widely used to study atopic asthma. Mouse OVA models have 
successfully mimicked many features of atopic asthma: eosinophilic airway respiratory 
inflammation, Th2 cell responses, and airway hyper-responsiveness, and have greatly 
contributed to our understanding of the immune mechanisms in atopic asthma [10]. So far 
only limited animal models of diisocyanate asthma can be regarded to be adequately 
successful for studies of TDI-induced asthma. Studies, most commonly in guinea pigs, have 
demonstrated the acute inhalational toxicity and immunogenicity of diisocyanates, as well as 
features characteristic of human asthma, including airway inflammation, AHR, and mucus 
hyper-secretion following sensitization and respiratory tract exposure [1, 11-12]. 
Interestingly, it has been reported an upper respiratory tract inflammation with 
predominantly neutrophilic infiltration in BALF [13]. 
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1.1 Definition of hypersensitivity and allergy 
  The term hypersensitivity is used to describe the objectively reproducible symptoms or 
signs initiated by exposure to a defined stimulus at a dose tolerated by normal persons [14-
15]. 
  Allergy is a hypersensitivity reaction initiated by specific immunologic mechanisms and 
can be antibody or cell-mediated. In the patient with symptoms from mucosal membranes in 
the airways and gastrointestinal tract, where the antibody belongs to the IgE isotype, these 
patients may be said to have IgE-mediated allergy. In a more chronic stage of IgE-initiated 
inflammation, the inflammatory reaction causing symptoms is dominated by allergen-
specific lymphocytes. Because of the hypersensitivity, the allergic symptoms can also be 
induced or aggravated by non-immunological factors such as infections, irritant, exercise 
and so forth [15]. In the conglomerate of non-IgE-mediated allergy, the inflammation can be 
mediated by allergen-specific lymphocytes, as in contact dermatitis, or by antibodies of the 
IgG isotype, as in anaphylaxis caused by immune complexes containing dextran and the 
classical serum sickness [15]. 
 
 
Fig.1. Allergy and hypersensitivity 
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Johansson, S.G., et al., A revised nomenclature for allergy. An EAACI position statement 
from the EAACI nomenclature task force. Allergy, 2001. 56(9): p. 813-24.
 
1.2 Asthma 
  Asthma is a disease characterized by episodic airflow obstruction that at least partially is 
reversible, lung inflammation and particularly airway’s hyper-responsiveness (AHR). Both 
the structure and function of the airways are altered in asthma. Airways’ remodeling in 
asthma induces not only structural changes but also fundamental changes in the relationships 
between and among various airway constituents [16]. Asthma resulting from immunological 
reactions should be called allergic asthma. Most cases are initiated by IgE antibodies, and if 
there is a wish to highlight that fact, a proper term is IgE-mediated allergic asthma. The 
importance of other immunologic mechanisms in initiating the inflammation associated with 
allergic asthma needs further investigation. About 80% of childhood asthma and > 50% of 
adult asthma has been reported to be allergic. The mechanisms initiating non-allergic asthma 
are not well defined, although similar inflammatory changes occur in both forms of asthma 
[15]. 
 
 
 
Fig.2. Allergy and asthma. 
Johansson, S.G., et al., A revised nomenclature for allergy. An EAACI position statement 
from the EAACI nomenclature task force. Allergy, 2001. 56(9): p. 813-24. 
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1.3 Occupational asthma 
  Occupational asthma (OA) is a type of asthma due to causes and conditions attributable to 
a particular work environment rather than to stimuli encountered outside the workplace [17]. 
As the most commonly reported occupational lung disease in many of industrialized 
countries [1-2], OA approximately accounts for 9% to 25% of cases of new-onset adult 
asthma [17-21]. There is a general agreement that OA can be distinguished as two types: 
immunologic OA (ie. allergic) and non-immunologic OA (ie. non-allergic). Immunologic 
OA appears after a latency period of exposure necessary for acquiring immunologic 
sensitization to the causal agent, though so far an immunologic mechanism for some agents 
has not yet been proven to induce asthma after a latency period. Non-immunologic OA 
generally occurs after acute exposure to high dose of irritants, is far less frequent and is 
characterized by lack of latency period [17]. This type of OA now has been termed as 
“irritant-induced asthma” [22], which includes reactive airway dysfunction syndrome after 
massive exposure to irritants, work-exacerbated asthma as a condition in which asthma is 
pre-existing or concurrent but exacerbated by occupational exposure [17]. The current 
thesis’ focus is on immunologic asthma. Occupational exposure has been shown to induce 
both respiratory and contact hypersensitivity reactions [3-5]. Like non-occupational asthma, 
OA is probably the result of multiple genetic, environmental and behavioral influences.  
  Many aspects of the pathophysiology of OA are controversial. Issues that frequently 
stimulate debate are the characteristics of immune responses induced by chemical 
respiratory allergens and the nature of the immunologic effector mechanisms [17]. 
 
1.4 Chemicals and asthma 
More than 350 agents have been reported to cause OA. Although there are fewer low 
molecular weight (LMW) chemicals than high-molecular-weight (HMW) agents in the list of 
occupational respiratory sensitizers, LMW still presents an important subset of etiologic 
agents, including approximately 100 separate chemical entities. Recent data indicate that 
LMW chemicals account for more new cases of OA caused by sensitization than HMW 
agents [17, 23]. Since there are about 30,000 registered chemicals, it can be estimated that 1 
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in 300 is asthmagenic. It is therefore reasonable to believe that asthmagenic chemicals have 
some important features in common. Quantitative structure-activity relations have been used 
to correlate chemical function with chemical structure, on the assumption that chemical 
structure is a determinant of chemical reactive properties and biological activity. So far the 
molecular mechanism for LMW respiratory sensitizers is still uncertain, therefore 
quantitative structure-activity relationships seems to be a relatively appropriate assumption 
[24-25]. 
 
1.5 High molecular weight (HMW) compounds 
  HMW compounds (MW > 1000 daltons) are groups of occupational agents like proteins, 
polysaccharides, and peptides that induce allergic response by producing specific IgE 
antibodies and sometimes specific IgG antibodies. In most instances, positive immediate 
skin test reactions can be elicited with extracts of the offending agents and specific IgE 
antibodies to these antigens can be detected. Clinically, the patients are usually atopic and 
have a history of allergic rhinitis and eczema. They usually describe asthma symptoms 
occurring within a few minutes of' exposure. Inhalation challenge tests with HMW 
occupational allergens induce an isolated immediate asthmatic reaction or biphasic reaction 
(immediate and late), seldom an isolated late asthmatic reaction. There are no differences in 
the pathogenetic mechanisms of asthma due to common occupational allergens and asthma 
due to common inhalant allergens such as house dust mite or pollen allergens [26-27]. 
 
1.6 Low molecular weight (LMW) compounds 
  Many LMW compounds (MW< 1000 daltons) have been shown to cause occupational 
asthma. In some instances, LMW agents are believed to act as haptens and form 
immunogenic complexes with carrier proteins. Specific antibodies to LMW chemicals are 
more difficult to detect though they are still likely to be involved in the pathogenesis of the 
disease. Especially, in the case of isocyanates, specific IgE antibodies are found in only a 
small proportion of affected subjects [26, 28-29]. 
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  Diisocyanates, highly reactive LMW compounds, are widely used in industry for the 
production of, for example, polyurethane foam, varnish, paint, elastomers, isolation 
materials, adhesives and many other products [6, 9, 30]. Diisocyanates contain two highly 
reactive groups (– N = C = O), which can react with – OH, – SH, and – NH2 groups of 
endogenous proteins [31-32]. It is known that diisocyantes are potential sensitizers and are 
able to bind to albumin, tubulin, keratin and glutathione in the skin or the mucosal surface 
[30, 33-38]. When the isocyanate groups (– N = C = O) of diisocyanate come into contact 
with an aqueous environment, amine groups ( – NH2) are formed spontaneously, with release 
of CO2 [39]. 
  With the increasing demand, the diisocyanate production has been in steady rise for 
decades [1, 3]. Diisocyante has been reported as one of the leading causes of occupational 
asthma, among which TDI, MDI and HDI are the most common triggers. Estimates on the 
prevalence of isocyanate-induced asthma among exposed workers varies from 0-15% [3, 7]. 
The principal feature of TDI-induced asthma is the airway inflammation with influx of 
lymphocytes, eosinophils and neutrophils [8]. This in turn leads to the variable AHR. 
Furthermore, TDI-induced asthma may share many features with allergic asthma, such as 
elevated total and specific IgE serum levels, airway inflammation characterized by activated 
CD4+ T cells, eosinophils and mast cells, increased levels of IL-4 and IL-5 and airway 
remodeling [9]. 
  OA due to diisocyanate exposure has following properties in many common aspects: the 
5% to 10% prevalence among workers in the industry, the predominant occurrence of late 
asthmatic reaction (isolated or late component of the biphasic reaction) on an inhalation 
challenge lest, the persistence of asthma despite removal from exposure in a large proportion 
of sensitized subjects, and the lack of predilection for atopic subjects. Despite the low 
prevalence of specific IgE antibodies to the hapten conjugates in affected subjects, the 
c1inica1 features of isocyanate- and plicatic acid-induced asthma are regarded as those of 
allergic diseases. Immune response mounted by these guinea pigs to diisocyanate protein 
conjugates was heterogeneous and involved multiple specificities for hapten, carrier protein, 
and new antigenic determinants. Because TDI is a highly reactive material, it is difficult to 
know what type of conjugate it might form when it is taken up by the body system. The 
inability to detect specific IgE and IgG antibodies may be due to our inability to produce an 
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appropriate antigen. The immunologic mechanism responsible for the asthmatic reaction has 
yet to be clearly elucidated [26]. 
  In contrast, mouse model-associated approaches are based on the finding that chemicals 
have the potential to cause respiratory allergy. Isocyanate skin exposure in various animal 
models induces systemic Th2-like sensitization that leads to asthma-like responses of the 
lung on subsequent specific inhalation challenges [6, 17, 40-41]. Interestingly, skin 
exposures may result in a greater lung inflammatory response after inhalation challenge in 
mice [42]. Data supporting the hypothesis that the skin may be a relevant site for systemic 
sensitization to certain occupational allergens in human beings are largely indirect. OA 
induced by MDI has been described in human beings, who appear to develop IgE-mediated 
asthma after dermal exposure to MDI [43]. 
  Although several efforts to use animal models have been made, the pathogenesis of TDI-
induced asthma remains largely unclear. In the first publication, we described a TDI mouse 
model with subcutaneous injection followed by intranasal challenge, which demonstrated a 
typical IgE-mediated Th2 immune response [44]. However, some authors observed a Th1-
like immune response characterized by an increase in the number of neutrophils and the 
increased levels of IFN-Ȗ and IL-8 [45]. They considered that IgE antibody to diisocyanate 
might be associated with high dose exposure and less severe outcome [23]. In order to 
further investigate immune response and the inflammatory phenotype which occurred in the 
development of TDI-induced asthma, we established a TDI asthma mouse model by 
epicutaneous sensitization and intranasal challenge, which is adjuvant free and was 
constructed on the base of type I allergy mouse model [46-49]. 
 
1.7 Some concepts in allergy and immunology 
 
1.7.1 Hapten 
  The concept of haptens emerged from the work of Karl Landsteiner[50] who also 
pioneered the use of synthetic haptens to study immunochemical phenomena. 
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  A hapten is a small molecule that can elicit an immune response only when attached to a 
large carrier such as a protein; the carrier may be one that does not elicit an immune 
response by itself. In general, only large molecules, infectious agents, or insoluble foreign 
matter can elicit an immune response in the body. Once the body has generated antibodies to 
a hapten-carrier adduct, the small-molecule hapten may also be able to bind to the antibody, 
but it will usually not initiate an immune response, only the hapten-carrier adduct can do 
this. Sometimes the small-molecule hapten can even block immune responses to the hapten-
carrier adduct by preventing the adduct from binding to the antibody, a process called hapten 
inhibition. 
 
1.7.2 Protein antigens and immune responses 
  Proteins are continually synthesized in the cells. These include normal proteins (self) and 
microbial invaders (non-self). A histocompatibility complex (MHC) molecule inside the cell 
takes a fragment of those proteins and displays it on the cell surface. (The protein fragment 
is sometimes compared to a sausage in a hot dog, and the MHC protein to the bun.) When 
the MHC-protein complex is displayed on the surface of the cell, it can be presented to a 
nearby immune cell, usually a T cell or natural killer (NK) cell. If the immune cell 
recognizes the protein as non-self, it can kill the infected cell, and other infected cells 
displaying the same protein [51]. 
 
1.7.3 MHC and antigen-presenting cells 
  There are two general classes of major MHC molecules: Class I and II. Class I MHC 
molecules are found on almost all cells and present proteins to cytotoxic T cells. Class II 
MHC molecules are found on certain immune cells themselves, chiefly macrophages and B 
cells, also known as antigen-presenting cells (APCs). These APCs ingest microbes, destroy 
them, and digest them into fragments. The Class II MHC molecules on the APCs present the 
fragments to helper T cells, which stimulate an immune reaction from other cells [51]. 
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1.7.4 T cells or T lymphocytes 
  T lymphocytes belong to a group of white blood cells known as lymphocytes, and play a 
central role in cell-mediated immunity. They can be distinguished from other lymphocyte 
types, such as B cells and natural killer cells (NK cells) by the presence of a special receptor 
on their cell surface called T cell receptors (TCR). The abbreviation T, in T cell, stands for 
thymus, since this is the principal organ responsible for the T cell's maturation. A large 
number of different subsets of T cells have been discovered, each with a distinct function 
[52]. 
 
1.7.5 T helper cell 
  T helper cells (Th cells) are a sub-group of lymphocytes that play an important role in 
establishing and maximizing the capabilities of the immune system. Th cells are involved in 
activating and directing other immune cells in immunologic processes, including maturation 
of B cells into plasma cells and activation of cytotoxic T cells and macrophages, among 
other functions. It is this diversity in function and their role in influencing other cells that 
gives T helper cells their name. These cells are unusual in that they have no cytotoxic or 
phagocytic activity; they cannot kill infected host cells (also known as somatic cells) or 
pathogens, and without other immune cells they would usually be considered useless against 
an infection. These cells are also known as CD4+ T cells because they express the CD4 
protein on their surface. Helper T cells become activated when they are presented with 
peptide antigens by MHC class II molecules that are expressed on the surface of Antigen 
Presenting Cells (APCs). Once activated, they divide rapidly and secrete small proteins 
called cytokines that regulate or assist in the active immune response. These cells can 
differentiate into one of several subtypes, including Th1, Th2, Th3, Th17, regulatory T 
(Treg) or follicular helper T (TFH) cells, which secrete different cytokines to facilitate a 
different type of immune response. The mechanism by which T cells are directed into a 
particular subtype is poorly understood, though signaling patterns from the APC are thought 
to play an important role [52]. 
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1.7.6 Mast cells 
  Mast cells are the main effector cells of especially the early phase of the allergic reaction 
and in immediate asthmatic response. Through antigen cross-linking to high affinity IgE 
receptors on the cell surface, mast cells discharge several groups of mediators, such as 
histamine. It has also been reported that mast cell-derived lipid mediators including 
leukotrienes and prostaglandins play an important role in the late asthmatic response and 
AHR [53-54]. Furthermore, mast cells can secrete inflammatory cytokines such as IL-4, IL-
5, IL-6, IL-13 and TNF-Į, which have a potential role in cellular infiltrates and airway 
inflammation [55]. 
Moreover, some studies in vitro demonstrated that mast cells produce various mediators 
such as transforming growth factor (TGF)-ȕ1 [56] and matrix metalloproteinases (MMPs) 
[57], which may contribute to the development of airway remodeling [58]. 
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Fig.3. Activation of T cells. 
The T lymphocyte activation pathway is triggered when a T cell encounters its cognate 
antigen, coupled to a MHC molecule, on the surface of an infected cell or a phagocyte. T 
cells contribute to immune defenses in two major ways: some direct and regulate immune 
responses; others directly attack infected or cancerous cells. 
http://www.niaid.nih.gov/topics/immuneSystem/Pages/response.aspx. Immune system, NIH 
publications. Last updated October 2, 2008. 
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2. AIMS OF THE STUDY 
 
The principal aims of this work were: 
 
1) To establish and evaluate asthma mouse models to study the phenotype of responses 
to TDI as compared to the responses to the protein allergens OVA and OVA peptide 
323-339. 
2) To define the in vivo and in vitro antigenicity or allergenicity of the protein allergen 
OVA and the synthesized OVA peptide 323-339. 
3) To study whether different sensitization routes result into different responses with 
respect to antibody production, cytokine secretion and inflammatory cell infiltration. 
4) To investigate the role of IgE in the inflammatory and bronchial responses to TDI. 
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3. MATERIALS AND METHODS 
 
3.1 Allergens and chemicals 
  In order to correctly interpret the different responses monitored in this study, it is 
imperative to use high quality chemicals and well defined allergens for the specific exposure 
and sensitization.  
  TDI (2,4 to 2,6-isomers; ratio, 80:20; lot S36694 311) was obtained from Merck-
Schuchardt, Hohenbrunn, Germany. Ovalbumin (electrophoretic purity 99%, lot 81F-8230) 
was purchased from Sigma Chemical Company, St Louis, MO, USA. Imject-alum (lot E164 
107) was obtained from Pierce Biochnology Inc., Rockford, IL, USA. Ovalbumin peptide, 
amino acid residues No. 323–339, was synthesized by semi-automatic peptide synthesizer 
(LKB Biochrom, Ltd, Cambridge, England) as described before by Johnsen and Elsayed [59] 
at the Allergy Research Group, Laboratory of Clinical Biochemistry, Haukeland University 
Hospital, Bergen, Norway. 
 
3.2 Experimental animals  
  BALB/c mice have been widely used for asthma and other allergy-related research, since 
they are high IgE responders and easily to acquire at lower cost. In addition, increasing 
amount of literatures cites the use of mouse models in studies of OA.  
Female BALB/c mice (approximately 20 g and 8 weeks old) were kept in a conventional 
animal house with 12-h dark/light cycles. They received tap water and pelleted pathogen-
free food ad libitum. All experiment procedures were approved by the local Ethical 
Committee for Animal Research. 
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3.3 Sensitization and challenge protocols 
  Animals were allowed to acclimatize at least for 1 week in order to avoid unnecessary 
influence on the results originated from the stress. In this thesis three different protocols 
were used. 
 
3.3.1 Subcutaneous sensitization and intranasal challenge protocol for TDI 
  Firstly, female BALB/c mice were sensitized by subcutaneous injection (SC) with 20 ȝl of 
neat TDI once, followed by 20 ȝl of TDI in olive oil (1:10) once a week for 2 weeks. 
Thereafter, the mice were challenged intranasally (IN) with 1% TDI dissolved in ethyl 
acetate:olive oil (1:4) for 3 consecutive days (see Publication I).  
 
Fig.4. The protocol of TDI mouse model used in Publication I. SC = subcutaneous injection, 
IN = intranasal challenge. 
 
3.3.2 Intraperitoneal sensitization and intranasal challenge protocol for OVA    and 
OVA 323-339 
  Female BALB/c mice were intraperitoneally injected with 25 μg OVA or OVA 323-339 
absorbed on 300 μg alum once a week for 3 weeks, followed by intranasal challenge with 20 
μl of 1% OVA and 1% OVA 323-339, respectively. Alum and saline control groups were 
sensitized and then challenged in a similar manner as the OVA 323-339 group. The protocol 
is illustrated as in following figure. The peptide (Pep) group is presented as an example to 
explain the protocols. IP: intraperitoneal injection, IN: intranasal challenge (see Publication I 
and II). 
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Fig.5. The protocols of OVA peptide or OVA mouse model used in Publication I and II 
 
3.3.3 Epicutaneous sensitization and intranasal challenge for TDI and OVA 
  After a two-week acclimatization period, female BALB/c mice were epicutaneously 
sensitized according to Vaali et al. [47] with minor modifications. Briefly, allergens or 
vehicles were added to lightly wounded skin once a week for total of 3 weeks. The 
concentrations of allergens in volume of 100 ȝl were used as follows: 1% TDI in acetone: 
olive oil (3:2, AOO), AOO and 0.1% OVA in saline. Mice were challenged intranasally (IN) 
with 25 ȝl of the same allergen or vehicle every other day for a total of 3 times. Using TDI 
as an example, the protocol is illustrated as follows (see Publication III):  
 
 
 
Fig.6. The protocol of improved TDI mouse model used in Publication III. EC = 
epicutaneous sensitization, Plets = plethysmographic recordings. 
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3.4 Sampling of serum and bronchoalveolar lavage fluid (BALF) 
  On the last day of our protocol, the mice were given intraperitoneal injections of Pentothal 
(sodium thiopental) and killed by right ventricular exsanguinations. The blood was collected 
and then centrifuged at 1000 g for 10 min. The serum samples were stored at - 20 °C until 
use. After right ventricular exsanguinations, the trachea was cannulated with a 20G catheter 
and the lungs were lavaged three times with aliquots of 0.5 ml of sterile saline per mouse. 
The collected BALF was centrifuged at 400 g, and the supernatant was stored at -20 °C for 
cytokine and antibody analysis. 
 
3.5 Quantification of total IgE  
  To evaluate whether the mice were sensitized, total IgE in the sera and BAL fluid was 
quantified with a sandwich ELISA protocol provided by mouse IgE ELISA Quantitation Kit 
(Bethyl Laboratories, Montgomery, TX, USA). The measurements were performed 
according to manufacturer’s manual. The detection limit of the kit was 3.9–250 ng/ml (see 
Publication I and II). 
 
3.6 Detection of specific antibodies to allergens in serum.  
  In order to characterize the sensitization of the mice, specific immunoglobulin IgE, IgG1 
and IgG2A to TDI, OVA and OVA 323-339 were assayed by in-housed ELISA as previously 
described [47]. As for the detection of IgE to OVA 323-339, biotinylated OVA 323-339-
BSA (EZ-Link NHHS-PEO4-Biotinylation Kit; Pierce, Biotechnology, Rockford, IL, USA) 
[47, 60] was applied. The results were expressed as optical density (OD) (see Publication II 
and III).  
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3.7 Quantification of IL-4 and IFN-Ȗ proteins 
  The most important markers for Th1 and Th2 balance were evaluated by IL-4 and IFN-Ȗ 
protein assays. These were quantified from both serum and BAL fluid by a sandwich ELISA 
protocol (R&D Systems, Minneapolis, MN, USA). Buffers and diluents used between steps 
in this assay were provided by the same company. The kit detection limits for IL-4 given by 
the manufacturer was 7.8-250 pg/ml and for IFN-Ȗ 9.4-600 pg/ml (see Publication I and II). 
 
3.8 Multiplex sandwich immunoassay of cytokine proteins 
  For more detailed characterization of the Th1 and Th2 balance, multiplex analyses of 8-
plex MILLIPLEX MAP Mouse Cytokine/Chemokine Panel (Millipore Corporate, Billerica, 
MA, USA) were performed strictly according to the manufacturer’s instruction using a 
Luminex xMAP system (Luminex Corporation, 12212 Technology Blvd Austin, TX, USA). 
Serum samples were diluted 1:1 for the measurement. Standard calibration curves ranged 
from 3.2–10,000 pg/ml (see Publication III). 
 
3.9 BALF cytology assays 
  For studies of target tissue pathophysiology, BALF was centrifuged at 1500 rpm for 15 
min, and the cell pellet was collected and re-suspended with 30 μl of PBS. Total cell count 
was done with a Burkers hemocytometer and then the rest of cells were equally smeared to a 
slide by Shandon Cytospin and Papanicolaou staining was conducted. Differential cell 
numbers were counted under light microscope (see Publication III). 
 
3.10 Spleen cell culture.  
  In order to evaluate whether OVA or OVA 323-339 can stimulate T cell proliferation, 
mice splenocytes were isolated and cultivated in the presence or absence of the immunogens. 
The spleens were minced into small pieces, splenocytes were dissected free and then 
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collected from interface after Ficoll-paque centrifugation. The viability of the collected cells 
was  95% by use of the trypan blue exclusion method. Separated splenocytes were cultured 
on 24-well cell culture clusters with saline or allergens in RPMI-1640 at 37 °C 5% CO2, 
final volume of 2 ml. Three days after initiating the culture, 100 ȝl of recombinant IL-2 (rIL-
2, 1 ȝg / ml) was added to each well. After 4 days cell culture, 200 ȝl of cells (2.5 × 106 cells 
/ well) in duplicate were cultured in 96-wells overnight by adding 20 ȝl of 0.05 mCi / ml 
[methyl-3H] thymidine. The cultures were investigated for primary proliferation responses as 
measured by 3H-thymidine uptake. The results were expressed as counts per minute (cpm) 
(see Publication II). 
 
3.11 Target tissue histology 
  To visualize roughly typical pathological findings in asthma mucus production was 
evaluated by histological staining. The lungs and hearts were removed en bloc and inflated 
with a similar volume of 10% buffered formalin (600 ȝl) at a constant pressure and then 
immediately soaked in the same solution for approximately 24 h, and thereafter embedded in 
paraffin [61]. Lung tissue sections (4 ȝm) were stained with haematoxylin and eosin (HE) 
and Periodic acid-schiff (PAS) (see Publication I, II and III). 
 
3.12 Major basic protein (MBP) evaluation 
  Immunohistochemical staining of sectioned lung tissue was performed with rabbit 
polyclonal antibody against murine MBP. Pictures were acquired with LEICA DMLB light 
microscope and LEICA DC 300 camera, later on, imported into Adobe Photoshop 7 (see 
Publication I and II). 
 
3.13 Morphometric analysis of airway thickness. 
  Bronchi with a diameter less than 250 μm presenting a smooth circular and oval profile 
were selected. Bronchial measurements were made at 250 × magnification using a LEICA 
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Q500 MC Qwin system as schematically illustrated in Publication I, Fig.1. Five mice from 
each group were enrolled in this measurement. The differences between individual groups 
were tested by one way ANOVA statistical analysis for multiple comparisons. 
 
3.14 Non-invasive whole body plethysmographic recordings 
  To monitor non-invasively the bronchial responses after TDI and allergen sensitization we 
used whole body plethysmograghic equipment (EMKA). With this non-invasive method the 
airway variable that best describes mouse asthma is Penh (enhanced pause in the breathing 
pattern). Using nebulized saline as baseline, we assayed increase in Penh by increasing 
concentrations of acetyl-ȕ-methylcholine chloride (methacholine, 5, 10, 20 and 40 mg/ml) 
and compared the results between the study groups. The measurements were performed for 1 
min by 4 min intervals for data collection, the degrees of bronchial hypersensitivity 
responses induced by allergen exposure could be assessed sequentially. The equipment 
allowed to simultaneously record maximum 4 groups of mice. Recordings were done 24 h 
before the first intranasal challenge and 24 h after the third intranasal challenge (see 
Publication III). 
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4. SUMMARY OF RESULTS FROM THE PUBLICATIONS 
 
4.1 Publication I 
  The hypothesis of pathogenesis in TDI-induced asthma is still controversial, both Th1 and 
Th2 dominant immune responses have been reported. In order to address this issue, we 
developed a murine model of TDI-induced asthma by subcutaneous sensitization followed 
by intranasal challenge. Inflammatory responses to the OVA and OVA peptide 323-339 by 
intraperitoneal sensitization and intranasal challenge were also investigated as positive 
controls. 
  Our results demonstrated a neutrophil-dominant inflammation with infiltration of a few 
eosinophils in the peri-bronchial and peri-vascular regions of the lung in the TDI asthma 
model. This was accompanied by hyperplasia / hypertrophy of cells lining the airways and 
mucus production as shown by HE staining. Positive immunohistochemical MBP staining in 
the parenchyma was also shown. Th2 cytokine IL-4 and IgE antibody production were 
significantly increased 5 days after last challenge while IFN-Ȗ level was below the detection 
limit. In contrast, eosinophil-dominant inflammation was observed and typical Th2 
responses were triggered in OVA and OVA 323-339 mice. Conclusion: the clear elevation of 
IL-4 and total serum IgE could allow to conclude a possible Th2-like dominated allergic 
response in TDI-exposed BALB/c mouse model but with a neutrophil-dominant pulmonary 
inflammation. 
 
4.2 Publication II 
  It has been reported that OVA peptide 323-339 was responsible for 25–35% of the 
BALB/c T-cell response to the intact OVA. Further, it is highly probable that OVA 323-339 
could be closely related to the peptide naturally created by the APCs during OVA 
processing. Moreover, Janssen et al. demonstrated that the immune-dominant epitope of 
OVA, e.g. OVA 323-339, accounts for 50% of the OVA-specific B-cell response and 60–
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70% of the OVA-specific T-cell response. So far little information has been acquired 
concerning whether OVA 323-339 could develop the same in vivo immune response as OVA 
did in allergen-treated mouse. 
  This part of our study aimed to investigate whether OVA 323-339 was the major antigen 
of OVA and could be regarded as a key peptide in the development of OVA-related asthma. 
Mice were treated with OVA and peptide OVA 323-339 equally as in publication I. 
Splenocytes from sacrificed mice were isolated and cultured under stimulus of each allergen 
or medium. 
  When evaluated by hematoxylin/eosin and MBP immunohistochemical staining, OVA 
and OVA 323-339 induced similar lung inflammation. Significant increase of serum total 
IgE and OVA-specific IgE were observed in OVA mice when compared to saline control, 
but no significant increase of OVA 323-339-specific IgE was observed in OVA mice. 
Interestingly, OVA 323-339 mice showed both higher serum levels of OVA-specific IgE and 
OVA 323-339-specific IgE. In addition, increased serum IL-4 and lower IFN-Ȗ were 
obtained in OVA323-339 mice as well as in OVA mice. The proliferative response to OVA 
was found in cultured splenocytes of both OVA and OVA 323-339 mice, while the similar 
proliferative response to OVA 323-339 was only observed in the splenocytes of OVA 323-
339-sensitized and challenged mice. Conclusion: OVA 323-339 induced a Th2-like response 
in the mouse model similar to OVA. However, unlike OVA, OVA 323-339 had in vitro a 
clearly limited immunogenic potency to activate OVA-sensitized and challenged mice 
splenocytes. 
 
4.3 Publication III 
  The mechanism responsible for TDI-induced asthma is not fully understood and the 
determinant for exposure remains far from clear. There are several possibilities for the 
subjects to become sensitized in the TDI industry and thereby finally develop into asthma. 
Skin sensitization is believed to be one of most important sensitization routes besides 
inhalation. Therefore type I allergy model was used to study the mechanism of bronchial 
hyperreactivity in TDI-induced asthma. This could better mimic the development and 
possible mechanisms of occupationally related asthma. In this context, we developed an 
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improved TDI asthma mouse model to validate the phenotype of pulmonary inflammation 
and immune responses. Mice were sensitized with TDI or OVA epicutaneously once a week 
for 3 weeks, and were then given intranasal challenge every other day for a total of 3 times. 
The control mice were treated similarly. On the days before the first and after the last 
intranasal challenge, pulmonary functions were tested by plethysmography system. TDI-
exposed mice exhibited a neutrophil-dominant pulmonary inflammation, in contrast to the 
eosinophil-dominant inflammation presented in OVA mice. Similar results were observed in 
the BALF differential cell counts. Both TDI and OVA mice had significantly increased AHR 
when evaluated by Penh, compared to respective controls. Augmented serum levels of IgG1- 
and IgE- antibodies were observed in TDI- and OVA-exposed groups. Moreover, both 
groups displayed elevated serum IL-5 protein levels. However, OVA group showed 
significantly increased IL-1ȕ protein. Conclusion: Increased TDI-specific IgE- and IgG1– 
antibodies may play important roles in the development of TDI-induced asthma mouse 
model like OVA-specific IgE- and IgG1-antibodies did in OVA mice, the TDI-induced 
neutrophil-dominant pulmonary inflammation, however, was clearly different from the 
response in OVA mice. 
  Dermal sensitization on its own could initiate pathophysiology of altered airway functions 
and, surprisingly, challenge with TDI after sensitization did not exacerbate bronchial hyper-
reactivity. This result stresses the importance of dermal sensitization in the development of 
TDI-induced asthma. 
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5. GENERAL DISCUSSION 
 
5.1 Immune and inflammatory responses in the TDI-induced asthma model 
  Understanding the pathogenesis of occupational asthma is a crucial step toward optimal 
prevention and management of the condition. In this respect, identifying the structural and 
biological airway characteristics that determine the potential for inducing airway 
sensitization is fundamental to the implementation of primary preventive strategies [23]. To 
our knowledge, there are only a few mouse models of TDI-induced asthma which can well 
describe the pathophysiology in the development of TDI-induced asthma up to now. 
Hitherto, the pathogenesis of occupational asthma caused by LMW agents, such as TDI still 
remains largely unknown [23]. So it is of interest to study the development of asthma by 
means of animal models, exploring the contradictory inflammatory phenotypes and immune 
responses postulated [6]. Clinically, assessment methodology for skin exposure is not as well 
developed as it is for exposure by inhalation. Isocyanate skin exposure has been documented 
in auto body shops and among spray painters using polyurethane products, despite the use of 
standard personal protective equipment, even in settings where airborne concentrations are 
minimal [62-64]. Further studies are needed to investigate the role of skin exposure at 
workplace in the mechanism of sensitization and the development of OA [17]. 
  The immune system must achieve a balance of sensitivity in order to respond to foreign 
antigens without responding to the antigens of the host itself. When the immune system 
responds to very low levels of antigen that it usually should not respond to, an 
immunological hypersensitivity response occurs. Immunological hypersensitivity is defined 
as the cause of allergy, which in the airways commonly refers to conditions or reactions 
associated with an IgE antibody-mediated response following antigenic exposure [65]. 
  Binding of specific IgE antibodies to hapten conjugated with human serum albumin has 
been reported in a low proportion of workers with ascertained OA caused by most LMW 
agents, including diisocyanates (0–39%). The presence of IgE antibodies specific to LMW 
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agents conjugates generally shows a very high specificity for OA, although they can be 
found in asymptomatic exposed workers as well [23]. 
  In the mouse IgE test, dermal exposure to a test chemical is followed by measurement of 
total serum IgE antibody level. An increase in total IgE is thought to imply that the chemical 
is a respiratory sensitizer [25]. The detection of Th2-type cytokines released from CD4 
lymphocytes during airway sensitization of an animal to a chemical is considered to be 
indicative of respiratory sensitization. IL-4, IL-5, IL-10 and IL-13 cause class switching to 
IgE production by B lymphocytes [25, 66] and the inhibition of IFN-Ȗ production. Cytokine 
profiling distinguishes Th2 responses, believed to be an integral mechanism in respiratory 
sensitization from Th1 responses which predominate in skin sensitization, known to involve 
delayed hypersensitivity (type IV) [25].  
  In our study, from both epicutaneous and subcutaneous TDI sensitization models, 
significantly increased serum IgE levels were observed (Publication I, Publication II) in 
company with increased serum IL-4 (Publication I) and IL-5 (Publication III). In contrast, 
we did not find any increase in IFN-Ȗ.  
  Allergic diseases including allergic asthma manifest many forms, for in instance, they can 
be defined as adverse health effects resulting from the stimulation of a specific immune 
response [67]. For example, selective type II (Th2) allergic responses such as respiratory 
hypersensitivity can be induced in susceptible persons after airway exposure to a chemical 
allergen. A variety of chemicals including various diisocyanates, acid anhydrides, and 
reactive dyes, can cause allergic sensitization of the respiratory tract associated with 
occupational asthma and other symptoms [6, 68-74]. Unlike typical protein allergens that 
cause asthma, diisocyanates are extremely reactive compounds and great uncertainty exists 
regarding the carrier proteins for these chemical haptens in vivo [1]. 
  The difference between the airway inflammation of diisocyanate asthmatic patients and 
common atopic asthmatic patients may reflect differences in the immune mechanisms central 
to pathogenesis. The most striking difference in the limited number of diisocyanate patients 
studied is the relative increase in neutrophil influx and IL-8 production [45, 75-76]. 
  So far, quite limited animal models of diisocyanate asthma have been applied. Most of the 
studies, commonly based on guinea pigs, have demonstrated the acute inhalational toxicity 
and immunogenicity of diisocyanates, and the features characteristic of human asthma, 
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including airway inflammation, airway hyperresponsiveness, and mucus hypersecretion 
following respiratory tract exposure and sensitization [1-2, 77-78].  
  More mechanistic studies have been limited by the lack of widely accepted animal models 
that replicate human diisocyanate asthma. Mouse models are well known to offer numerous 
advantages, including the availability of genetically manipulated strains and a wide array of 
diagnostic molecular tools. However, it has been difficult to evoke diisocyanate-induced 
airway inflammation in mice, potentially related to poor delivery of the highly reactive 
diisocyanates to the lower airways, as well as the difficulties measuring airway 
hyperresponsiveness. In addition, these present models vary greatly in regard to mice strain, 
the type of diisocyanates used, the route, timing, and dosing of diisocyanate sensitization and 
challenge, and therefore the subsequent differential inflammatory and physiologic responses. 
  In our study, we assessed the recruitment of neutrophils, eosinophils, macrophages and 
lymphocytes in BALF. A significant increase in BALF neutrophils was found in TDI-
sensitized and –challenged mice, but we failed to show macrophage-derived, increased IL-8, 
G-CSF or MIP-2 levels in serum, nor indication of increase VGEF production, latter of 
which is related to bronchial asthma (Publication III). However, consistent neutrophil-
dominant inflammatory type was also observed in both epicutaneously and subcutaneously 
sensitized TDI mice models. The mechanisms for the infiltration of neutrophils are still 
uncertain and may be partially due to the direct stimulation to the bone marrow or the non-
specific effect of the allergen like toxic response. 
  The mechanisms of absence of immune responses may vary and involve complex 
immunological mechanisms including absent or insufficient co-stimulatory signals from 
antigen presenting cells. 
 
5.2 OVA peptide 323-339 and OVA-induced asthma 
  Egg is an essential ingredient in human and animal food and it is very difficult to totally 
eliminate its exposure [79]. OVA, which constitutes approximately 58% (w/w) of the entire 
hen’s egg white extract, is the most dominant ingredient of the five major allergens of egg 
white and is universally used as the main allergen in establishing different animal models of 
asthma, food and dermal allergy. The complete amino acid sequence of OVA has been 
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elucidated. OVA’s allergenic epitopes were mainly determined by the primary structure and 
are dependent on a certain peptide chain length [59-60, 80]. Among many egg white 
proteins, OVA 323-339 as well as intact OVA, was reported to encompass B cell epitopes 
which were recognized by specific IgE antibodies. The OVA peptide 323-339 sequence was 
also demonstrated to include CD4+ T cell epitopes, which were restricted by the MHC class 
I-Ad molecule in mice [81-83], and was considered to encompass at least one B cell epitope 
[84-85]. Furthermore, the OVA specific T cell line from hen’s egg allergic patients was able 
to recognize OVA 323-339 presented by HLA-DR10 [81, 86]. 
  OVA is widely used as a model protein in structural as well as immunological studies[79]. 
Murine models have been broadly employed to study atopic asthma. Mouse ovalbumin 
models have successfully duplicated many features of atopic asthma: eosinophilic airway 
inflammation, Th2 T cell responses, and airway hyperresponsiveness, and have greatly 
contributed to our understanding of the immune mechanisms in atopic asthma [1, 10]. 
  OVA 323-339 has been used extensively to study the nature of class II MHC-peptide 
binding and T cell activation [87-91]. It has been reported that OVA peptide 323-339 was 
responsible for 25-35% of the BALB/c T-cell response to the intact OVA, and it is highly 
probable that OVA 323-339 was closely related to the naturally created peptide by the APCs 
during OVA processing [59, 82, 85, 92]. However, Janssen et al. demonstrated that the 
immunodominant epitope of OVA, e.g. OVA 323-339, accounts for 50% of the OVA-
specific B cell response and 60-70% of the OVA-specific T cell response [93]. So far, there 
is only a small amount of available information on in vivo immune responses in OVA 323-
339 treated animals. Kearney et al. reported that systemic injection of OVA or OVA 323-
339 in a T cell transfer model induced a rapid and strong, but transient DO11.10 T cell 
proliferation [94]. They also described that the induction of more local and less transient 
responses by the subcutaneous administration of OVA 323-339 in Freund’s Complete 
Adjuvant, resulting in a significantly enhanced T cell response upon in vitro stimulation with 
OVA 323-339 [94-95]. Knowledge on the immunogenicity of allergens is important and 
mandatory for establishing modern therapeutic methods for the treatment of allergy. 
  In our study, OVA-treated mice illustrated an increased total and OVA-specific IgE 
production in serum, while OVA 323-339 mice showed a significant increase in the 
production of OVA 323-339-specific IgE. Interestingly OVA-specific IgE also was detected 
in OVA 323-339 sensitized mice, which was consistent with the data from Renz et al [96]. 
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But, by ELISA detection using OVA 323-339 conjugated to BSA we did not find increased 
OVA323-339-specific IgE in OVA sensitized mice. In contrast, Renz and his collegues 
found 50% and 80% reduction in OVA-specific IgE from the serum samples of OVA-
sensitized and OVA 323-339 sensitized mice after pre-incubation with OVA 323-339. This 
could be explained by the fact that in vivo OVA 323-339 might bind to carrier protein and 
acquire weak immunogenicity for antibody production (low total IgE in OVA 323-339 
sensitized mice). Furthermore, the low detectable concentration of anti-OVA323-339 IgE in 
OVA sensitized mice might imply that the OVA amino acid sequence 323-339 may not be as 
strong immunogen as intact OVA. 
  Very low specific-IgG1 to OVA and OVA 323-339 were detected as well as IgG2A in 
serum and BALF suggested IgE-mediated response may dominate in the immune response 
triggered by OVA and its peptide.  
  Increased IL-5 but not IL-4 indicated that the dermal sensitization route with OVA may 
activate the Th2 response by different cytokines rather than that of intraperitoneal 
sensitization route (IL-4 dominant activation). Lower IFN-Ȗ in serum can distinguish a Th2 
immune response to both OVA and OVA 323-339 from a Th1 cell-mediated reaction. 
 
5.3 Immunoglobulin G and occupational asthma 
  A high level of specific IgG-antibodies to diisocyanates has been shown to be closely 
correlated with the level of workplace exposure, and is more sensitive, but less specific than 
IgE in identifying occupational asthma [23, 97]. 
  Guinea pig models historically used to study TDI-induced asthma, display both immediate 
and late-onset airway responses as well as dose-dependent IgG-antibody-specific responses 
[33, 77, 98]. Specific IgG antibodies have at least been shown to reflect exposure, although 
IgG antibodies do not reflect airway hypersensitivity [33]. 
  In our intraperitoneal study, neither OVA nor OVA 323-339 induced an increased 
production of IgG1- and IgG2A-antibodies. However, in the epicutaneous study, both OVA 
and TDI mice demonstrated that increased IgG1–antibodies paralleled IgG2A, which may 
suggest an immune response specific to the epicutaneous sensitization route (sensitization 
route-dependent phenomenon) or there was an immune tolerance that occurred. 
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5.4 Proliferation responses to OVA and OVA peptide 323-339 (Publication I) 
  In the mouse model of intraperitoneal sensitization and intranasal challenge, splenocyte 
stimulation with OVA induced an increased proliferative response as observed in both OVA 
and OVA 323-339-sensitized and challenged mice, while proliferation to OVA 323-339 only 
occurred in splenocytes of the OVA 323-339 mice and not in the OVA mice. Accordingly, 
cells stimulated with control culture medium demonstrated very low thymidine incorporation 
when compared with the responses to OVA and OVA 323-339 stimulation. Our presented 
proliferative results are consistent with the results of Janssen et al. who demonstrated that 
OVA 323-339 induced a proliferative response in cell cultures from OVA-challenged 
animals [99].  
  The proliferative response assay demonstrated that OVA 323-339 in vitro stimulation did 
lead to splenocyte proliferation and activation in cultivated cells. This could imply that small 
peptides such as OVA 323-339 can play their role by being presented and expressed on the 
membrane surface of activated splenocytes in the way same as in OVA mice. This is also 
consistent with previous ideas: OVA and OVA 323-339 encompassed CD4+ T cell epitopes, 
which were restricted by the MHC class I-Ad molecule in mice [81-83], and was considered 
to share at least one B cell epitope [84-85]. 
 
5.5 Airway Hyper-Responsiveness and Penh (Publication III) 
  Various alternative approaches for assessing AHR have been reported. Non-invasive 
methods based on single- or dual-chamber plethysmography appear to have much merit 
[100-101]. A whole-body plethysmography technique, which has gained considerable 
popularity, can be performed in un-anaesthetized and unrestrained mice by means of 
measurement of the dimensionless parameter known as enhanced Pause (Penh). It is the 
measured length of time between inspiratory and expiratory air and describes breathing 
difficulties [102]. Unfortunately this technique has limitations in models associated with 
extensive parenchymal disease, in which abnormalities may correlate poorly with airway and 
 39 
 
tissue mechanical properties [103]. The method has therefore been the subject of extensive 
criticism [104-106] and has fallen into disfavour, even though many of the criticisms in part 
can be answered [107]. Nevertheless, as a pulmonary function parameter, Penh may still 
have value in screening procedure and certainly proved to be useful for assessing AHR in 
our low-level challenge model, in which parenchymal disease is not considered to be a 
confounding factor [108]. 
  The ventilatory function is a composite index of airway obstruction [109]. Penh, as a 
parameter evaluating ventilator function by unrestrained whole body plethysmograph, can 
assess the changes in the ventilatory patterns and partially reflect degree of bronchial 
obstruction [110]. In our study, significant increase in Penh after intranasal challenges 
(compared to controls, TDI p = 0.0018 and OVA p = 0.0208) suggested an asthmatic 
response took place in the airways. The increased Penh before intranasal challenge (TDI p = 
0.077 and OVA p = 0.0315 vs their controls respectively) indicated that this asthmatic 
response seems to start after repeated epicutaneous sensitizations instead of after intranasal 
challenge. This phenomenon implied that AHR may have been triggered earlier than the first 
intranasal challenge, namely initiated by epicutaneous TDI sensitization. The subsequent 
intranasal challenge may have induced tolerance as suggested by the increased serum IgG2A 
immunoglobulin level. This finding was somehow similar to that of Vanoirbeek and his 
colleagues [110]: with the increase of challenge by times, the AHR decreased, possibly 
caused by induction of tolerance.  
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6. CONCLUSIONS 
 
1) TDI can in BALB/c mice induce a similar Th2-like immune response and AHR but a 
more pronounced neutrophil-dominant bronchial inflammation, rather than the 
eosinophilic inflammation in response to OVA / OVA peptide 323-339. 
2) OVA peptide 323-339 can both in vivo and in vitro express the major 
immunogenicity of OVA and induce a typical Th2 immune response in the BALB/c 
mouse model. In vivo, amino acid sequence 323-339 of intact OVA is not well 
expressed as a dominant antigen epitope. 
3) Different sensitization routes do not change the phenotypes of both the TDI- and 
OVA-induced responses in the BALB/c mouse model. 
4) Our results from the BALB/c mouse model may not allow characterizing the role of 
IgE in the airway responses to TDI. 
5) Intranasal challenge with TDI after epicutaneous sensitization did not exacerbate 
bronchial hyper-reactivity. 
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7. FUTURE RESEARCH PERSPECTIVES 
1) To investigate whether the use of anti-IgE-antibodies can inhibit the release of 
inflammatory mediators and to investigate further the role of IgE in the 
development of TDI-induced asthma both in vivo and in vitro. 
2) To establish allergen or chemical-conjugate sensitized T cell and B cell lines 
(splenocyte) and to investigate further the potential role of allergens and 
chemical-conjugate in T cell activation, the secretion of cytokines and 
antibodies in vitro. 
3) Further studies should be done on the mechanisms leading to the neutrophil 
infiltration into the target airway tissue. 
4) It would be of interest to study the cross-reactivity between different 
isocyanates such as HDI, MDI and TDI using the established mouse models. 
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